RecruitingNCT07363525

Michigan Initial Experience Using Tigertriever for Thrombectomy


Sponsor

Henry Ford Health System

Enrollment

150 participants

Start Date

Jan 15, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
  • Tigertriever was used as the first line treatment in the target vessel.
  • A signed informed consent.
  • Age ≥ 18.

Exclusion Criteria2

  • Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.
  • \. pre-stroke disability (pre-stroke mRS ≥ 2).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMechanical Thrombectomy

You will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data.


Locations(1)

Henry Ford Hospital

Detroit, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07363525


Related Trials